Actuate Therapeutics, Inc. Common stock (ACTU) Deep Dive Video
Summary
Actuate is a clinically promising but financially fragile oncology bet, where elraglusib’s pancreatic cancer survival data offers major upside if the company can survive its near-term cash cliff.